Business
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
SOUTH SAN FRANCISCO, Calif., June 25, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced its participation at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society, a leading Ataxia-Telangiectasia (A-T) patient advocacy group based in the United Kingdom. Taking place June 25-27, 2025 at Loughborough University in the U.K., key o
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/f44b0bc6847eb3b1ffd4bf57d7b580d8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fQtiMuIyPyvL8B_OvHyVUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f44b0bc6847eb3b1ffd4bf57d7b580d8","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Z2BX_VdW6B6bNjrqpKOsxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f44b0bc6847eb3b1ffd4bf57d7b580d8","width":1121,"height":442}},"lazy":false},{"type":"text","content":"Phase 3 NEAT enrollment momentum continues with 99 total participants enrolled to date","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 25, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced its participation at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society, a leading Ataxia-Telangiectasia (A-T) patient advocacy group based in the United Kingdom. Taking place June 25-27, 2025 at Loughborough University in the U.K., key opinion leaders (KOLs) will present post hoc data analyses from the company’s prior Phase 3 ATTeST clinical trial of its lead asset, eDSP, for the treatment of patients with A-T. Additionally, Quince management will provide an overview of its pivotal Phase 3 NEAT clinical trial.","length":795,"tagName":"p"},{"type":"text","content":"Highlights of A-T Clinical Research Conference Presentations","length":60,"tagName":"p"},{"type":"text","content":"KOLs will present the following data and information at the upcoming A-T Clinical Research Conference:","length":102,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Endocrine and Metabolic Events in Patients with A-T Treated with eDSP: William Whitehouse, M.D., Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, England, recently retired Consultant Pediatric Neurologist at Nottingham Children’s Hospital, Nottingham University Hospit...